Director Bigal Marcelo buys 1,512 shares of PCRX at $13.25 as stock -63.1% from 52-week high; cluster of 4 other insiders also bought within 14 days.
Director Bigal Marcelo purchased 1,512 shares at $13.25 on 2024-08-16, increasing his holdings by 17.5% to 10,142 shares total. The purchase occurred after a sharp drawdown: the stock is -63.1% from its 52-week high and down 54.8% over the past 90 days, creating a depressed valuation context. Notably, 4 other insiders also bought within the past 14 days, indicating a clustering pattern of insider accumulation during weakness. The company's fundamentals remain intact with $178.0M revenue and $18.9M net income in the latest quarter, suggesting the buying may reflect conviction in value at depressed prices rather than concern about near-term prospects.
Director Bigal Marcelo buys 3,400 shares of PCRX at $12.01; stock down 60.1% in 90 days; cluster of 2 other insider buys within 14 days.
Bigal Marcelo purchased 3,400 shares at $12.01, increasing his holdings by 65.0% to 8,630 shares total. The timing coincides with a cluster pattern: 2 other insiders also bought within the past 14 days, suggesting coordinated or simultaneous conviction at current price levels. The stock has experienced severe price deterioration—down 60.1% over 90 days and 67.8% from its 52-week high of $38.18—creating a significant gap between the director's entry point and peak valuation. Against this backdrop, the company maintains modest fundamentals with annual revenue growth of 1.2% and a P/E of 8.91, leaving unclear whether the cluster buy reflects oversold opportunity identification or acquisition by insiders at depressed levels following a sharp drawdown.
